TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05875870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daylight exposure combine walking
Description: 1. Out-door of bright-light exposure in the morning (36 min/day, 7 times/week) for six weeks.~2. Tailored to the individual patient with moderate intensity of walking (3 sessions/week) for six weeks. Duration of each session depends on one-on-one exercise consultation via communication software (LINE App). The duration of walking in week 1 is 15 minutes, then increasing 5 minutes each week if the patient has tolerance. If the patient cannot tolerate the duration, the coach will instruct to keep the same duration for the following week. Basically, the goal of duration in week six is 40 minutes.~3. Weekly exercise consultation via communication software (LINE App).~4. Teaching strategy includes one-on one instruction (hard-copy of teaching manual), video, and webpage.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercise
Description: The stretching exercise includes two movements for the upper body and two movements for the lower body, 10 minutes each time, three times a week, for 6 weeks.~The researcher will explain to the participants about how to perform the stretching exercise, according to an instruction manual (hardcopy) for the exercise regimen.~A video is shown to the participants (the content same as hardcopy of education manual).
Study: NCT04949620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REThink therapeutic game
Description: REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention for the reduction of emotional symptoms in children and adolescents.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online parenting program
Description: The online parenting intervention consists of a newly developed parenting program, including rational emotive behavioral therapy and schema therapy principles
Study: NCT05602688

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lemon Balm Supplement
Description: Oral 200 mg Lemon Balm supplement tablet Twice a day for three-weeks
Study: NCT05216965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW2821
Description: All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
Study: NCT06081907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363
Description: IBI363 is based on the 3+3 model with a dose of 1 mg/kg Q3W. IBI325, 20 mg/kg Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363
Description: IBI363 is based on the 3+3 model with a dose of 1.5 mg/kg Q3W. IBI325, 20 mg/kg Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363
Description: IBI363 is based on the 3+3 model with a dose of 600 μg/kg Q2W. Lenvatinib, 8mg QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363
Description: IBI363 is based on the 3+3 model with a dose of 1000 μg/kg Q2W. Lenvatinib, 8mg QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363
Description: The recommended dosages for IBI363, IBI325, and Lenvatinib in Phase Ib will be determined based on a comprehensive assessment of safety, efficacy, and other data obtained from the safety introduction portions of both Phase Ia (Part A) and Phase Ib (Part B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363
Description: The recommended dosages for IBI363, IBI325, and Lenvatinib in Phase Ib will be determined based on a comprehensive assessment of safety, efficacy, and other data obtained from the safety introduction portions of both Phase Ia (Part A) and Phase Ib (Part B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363
Description: The recommended dosages for IBI363, IBI325, and Lenvatinib in Phase Ib will be determined based on a comprehensive assessment of safety, efficacy, and other data obtained from the safety introduction portions of both Phase Ia (Part A) and Phase Ib (Part B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363
Description: The recommended dosages for IBI363, IBI325, and Lenvatinib in Phase Ib will be determined based on a comprehensive assessment of safety, efficacy, and other data obtained from the safety introduction portions of both Phase Ia (Part A) and Phase Ib (Part B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363
Description: The recommended dosages for IBI363, IBI325, and Lenvatinib in Phase Ib will be determined based on a comprehensive assessment of safety, efficacy, and other data obtained from the safety introduction portions of both Phase Ia (Part A) and Phase Ib (Part B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363
Description: The recommended dosages for IBI363, IBI325, and Lenvatinib in Phase Ib will be determined based on a comprehensive assessment of safety, efficacy, and other data obtained from the safety introduction portions of both Phase Ia (Part A) and Phase Ib (Part B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363
Description: The recommended dosages for IBI363, IBI325, and Lenvatinib in Phase Ib will be determined based on a comprehensive assessment of safety, efficacy, and other data obtained from the safety introduction portions of both Phase Ia (Part A) and Phase Ib (Part B).
Study: NCT04539730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: 266 mg or 20 ml Liposomal Bupivacaine injectable solution

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drug: SoC Ropivacaine
Description: 0.5% (5mg/mL) 20 mL single dose SOC anesthetic Ropivacaine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drug: SoC Ropivacaine
Description: 0.5% (5mg/mL) 20 mL single dose SOC anesthetic Ropivacaine.
Study: NCT06494995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: a PD-1/CTLA-4 dual antibody
Study: NCT05602688

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Matched Placebo
Description: Matched placebo tablet Twice a day for three-weeks
Study: NCT04978649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allisartan Isoproxil
Description: Allisartan Isoproxil 240mg daily will be used to lower BP to below 120 mm Hg systolic.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Allisartan Isoproxil
Description: Allisartan Isoproxil 240mg daily will be used to lower BP to below 120 mm Hg systolic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).
Study: NCT06443307

Intervention type: DRUG
Intervention: Irinotecan Liposome
Description: The experimental group will collect data from patients treated with Nal-IRI as the chemotherapy regimen. It is recommended to use according to the label, clinical practice shall prevail.

Intervention type: DRUG
Intervention: Irinotecan Liposome
Description: The experimental group will collect data from patients treated with Nal-IRI as the chemotherapy regimen. It is recommended to use according to the label, clinical practice shall prevail.

Intervention type: DRUG
Intervention: Irinotecan Liposome
Description: The experimental group will collect data from patients treated with Nal-IRI as the chemotherapy regimen. It is recommended to use according to the label, clinical practice shall prevail.

Intervention type: DRUG
Intervention: Irinotecan Liposome
Description: The experimental group will collect data from patients treated with Nal-IRI as the chemotherapy regimen. It is recommended to use according to the label, clinical practice shall prevail.
Study: NCT06494995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: a PD-1/CTLA-4 dual antibody

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy
Description: Low-dose radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy
Description: Low-dose radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: selected leisions to treat with stereotactic radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine metronomic chemotherapy
Study: NCT05059314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brisk walking (moderate physical activity)
Description: 1. Warm up and cool down~2. Brisk walk (30 mintues each session per week 5 days)~3. Week 1 to 6
Study: NCT05213091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otago Exercise Programme
Description: The first four weeks will be Otago Exercise Programme training and practice. For the next weeks, there will be institution visits and telephone interviews. Individuals will be given an Otago Exercise Programme training booklet, exercise chart and exercise diary to better manage this process. The research will be conducted in small groups (average 6-8).
Study: NCT06358833

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endodontic needle (EN)
Description: the irrigation of root canals will be done with 2.5 % sodium hypochlorite. The delivery of the irrigant will be done using 27G side-vented endodontic irrigation needles (Omega, Inc). The tip of the needle will be pre-measured and positioned within 1 millimeter of the working length. No activation of the irrigant will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endodontic activation (EA)
Description: the irrigation of root canals will be done with 2.5% sodium hypochlorite. The delivery of the irrigant will be done using 27G side-vented endodontic irrigation needles (Omega, Inc). The irrigant will be activated with ultrasonic energy using the Endo-1 Ultrasonic Endo Activator (Guilin Woodpecker, Guilin, China). The tip of the Endo-1 Ultrasonic Endo Activator device will be pre-measured and kept within 1 mm from the working length. The manufacturer's instructions regarding irrigant activation will be followed.
Study: NCT05422508

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG1111 (BARICELA)
Description: 0.5ml, single dose, subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VARIVAX
Description: 0.5ml, single dose, subcutaneous injection
Study: NCT06501651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Description: Sacubitril/Valsartan is a novel antihypertensive medication composed of an angiotensin II receptor blocker (ARB) Valsartan and a neprilysin inhibitor Sacubitril in a 1:1 molar co-crystal form. Sacubitril is a prodrug that, once ingested, is metabolized by esterases into its active form, which inhibits neprilysin activity. Neprilysin has various substrates, including natriuretic peptides and angiotensin II (Ang II). By inhibiting neprilysin, the levels of natriuretic peptides that have antihypertensive and organ-protective effects are increased. The other component, Valsartan, effectively inhibits the Ang II type 1 receptor (AT1R), providing additional antihypertensive and organ-protective effects. The co-crystal structure ensures that Sacubitril and Valsartan have similar absorption and elimination rates, thereby synchronizing their pharmacological effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan, effectively inhibits the Ang II type 1 receptor (AT1R), providing both antihypertensive and organ-protective effects.
Study: NCT04754451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group L
Description: Attach two lidocaine patches for 12 hours, one above and below the incision site.
Study: NCT05341271

Intervention type: OTHER
Group type: OTHER
Intervention: Experimental: digital reminiscence group (DRG)
Description: Experiment group A accepted the digital reminiscence group planned by the official account platform of line as the medium, the theme and content, it is planned to consider the development of the life cycle, and the experience of the thematic review will induce the motivation of the participants, since childhood life, study The design of eight unit themes such as stage, work and emotional family and festival life, and special life events; at the same time, it can adapt to the psychological adaptation behavior of the participants, review their life development stages according to the life development process, and pay attention to the interpersonal interaction carried out by the current group Negative emotional or symptomatic behavior with dialogue, and directing and dealing with life experiences

Intervention type: OTHER
Group type: OTHER
Intervention: Experimental: general reminiscence group (GRG)
Description: Experiment group B participated in general reminiscence group (GRG)~, using actual nostalgic objects or utensils to carry out activities. The theme and content are intended to be considered in the context of life cycle development, and the experience of thematic retrospectives induces the motivation of participants, since childhood. The design of eight unit themes, including the stage of study, work and emotional family and festival life, and special events in life; at the same time, it can adapt to the psychological adaptation behavior of the participants, review their life development stages according to the life development process, and pay attention to the current group activities. Interpersonal interaction and dialogue, and negative emotional or symptomatic behaviors that guide and process life experiences
Study: NCT05337254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine
Description: Dihydroergotamine intranasal powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine
Description: Dihydroergotamine intranasal powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine
Description: Dihydroergotamine intranasal powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroergotamine
Description: Dihydroergotamine intramuscular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroergotamine
Description: Dihydroergotamine intranasal spray
Study: NCT06413862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: The experimental group was slowly injected with ciprofol for 30 seconds (0.4mg/kg, Haisike Pharmaceutical Co., Ltd., Liaoning, China, batch number 20220911).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The control group was slowly injected with propofol for 30 seconds (2mg/kg, Guorui Pharmaceutical Co., Ltd., Sichuan, China, batch number 22102914).
Study: NCT05707091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low level laser therapy and conventional therapy
Description: One group treated with low level laser therapy along with conventional therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: Group B treated with ems and exercises
Study: NCT04852848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect2Test Intervention
Description: Brief assessment based feedback and motivational interviewing intervention
Study: NCT04852120

Intervention type: OTHER
Intervention: No intervention
Description: Compound Sodium Picosulfate Granules administered by the patient prior to X-ray examination, endoscopy or surgery when judged clinically necessary in accordance to usual practice consistent with the local prescribing information.
Study: NCT05439499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-437c, Letrozole or anastrozole, Goserelin acetate
Description: FCN-437c：available in 25mg and 100mg capsules for oral administration on an empty stomach. 200mg once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment until progressive disease。Letrozole or anastrozole：Letrozole 2.5 mg or anastrozole 1 mg once daily；Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Letrozole or anastrozole, Goserelin acetate
Description: Placebo：available in 25mg and 100mg capsules, and is administered in the same way as FCN-437c。~Letrozole or anastrozole：Letrozole 2.5 mg or anastrozole 1 mg once daily；~Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
Study: NCT05217771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High tone power therapy group
Description: patients in this group will receive High tone power therapy from 30 to 60 minutes, 3 session /week for 4 weeks with total sessions at least l0 sessions and self-stretch for hand and shoulder.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High tone power therapy group
Description: patients in this group will receive High tone power therapy from 30 to 60 minutes, 3 session /week for 4 weeks with total sessions at least l0 sessions and self-stretch for hand and shoulder.
Study: NCT05677074

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: The tolerance of fish oil is tested using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cod oil
Description: The tolerance of cod oil is tested using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill oil
Description: The tolerance of krill oil is tested using two methods: skin-prick-test and Basophil Histamine Release Assay. (We were unable to acquire enough liquid krill oil to perform oral provocation with this supplement).
Study: NCT04636619

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonic polypectomy
Description: Cold snare resection of colorectal polyps

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online training course
Description: Polypectomy technique online course
Study: NCT05104580

Intervention type: DEVICE
Intervention: Quantitative Flow Ratio derived PPG
Description: From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2.

Intervention type: DEVICE
Intervention: Quantitative Flow Ratio derived PPG
Description: From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2.

Intervention type: DEVICE
Intervention: Quantitative Flow Ratio derived PPG
Description: From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2.
Study: NCT05879042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching
Description: Participants will be placed in the maximum dorsiflexion position of the ankle of the dominant side lower extremities. At this last point, it will be held in a static position for 30 seconds. A total of 10 repetitions will be done, with 5-10 seconds rest between repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching
Description: Participants will be positioned by placing their hands on the edge of the standing wall. They will be asked to try to increase normal ankle motion in a controlled manner using their own body weight. The stretching position will be held for 30 seconds and a total of 10 repetitions will be done. There will be 5-10 seconds rest between repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF Stretching
Description: For the lateral head of the gastrocnemius muscle, the dominant side lower extremities of the participants will be placed in the extension-adduction-external position. For the medial head of the gastrocnemius muscle, the dominant side lower extremities of the participants will be placed in the extension-abduction-internal rotation position. Participants will be asked to actively go as far as they can in the opposite direction from the starting position (flexion-abduction-internal rotation for the lateral head; flexion-adduction-external rotation for the medial head). When the participant returns to the starting position after reaching the final point, the practitioner will apply the hold-relax technique and will be asked to stay in this position for 10 seconds.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham stretching
Description: Sham stretching will be applied to the calf area. While the participant is lying prone, they will wait 30 seconds in a static position without applying any stretching to the calf area before reaching the end point of the joint range of motion.
Study: NCT05357300

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Nerve Stimulation
Description: Implant of percutaneous leads for peripheral nerve stimulation of the rami dorsales of the SIJ and gluteal or abdominal implant of impulse generator
Study: NCT05679635

Intervention type: DEVICE
Group type: OTHER
Intervention: Evone
Description: The conventional tube adapter (CTA) from the Evone ventilator (Ventinova Medical B.V., Eindhoven, The Netherlands), equipped with an tracheal pressure measurement catheter will be connected to the tracheal tube of intubated intensive care unit patients. Subsequently tracheal pressure values will be displayed and recorded from the ventilator.

Intervention type: DEVICE
Group type: OTHER
Intervention: Evita Infinity V500
Description: Displayed airway pressure values will be directly recorded from the Evita Infinity V500 ventilator (Dräger Medical, Lübeck, Germany)
Study: NCT05204966

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: AI analysis
Description: 1. Bottle feeding filming~   - With a camera that can measure depth, take a video of feeding milk from a bottle for 5-10 minutes.~2. NOMAS (Neonatal Oral-Motor Assessment Scale) evaluation~   * Evaluate NOMAS with bottle feeding video by certified evaluators.~  * NOMAS, developed by Marjorie Meyer Palmer in 1983, is an evaluation method for dysphagia applicable to infants under 48 weeks of PMA.~3. Implementation of video analysis using deep learning (A) Analysis method - Implement a deep learning network that sets keypoints of faces and environments related to swallowing and detects specified keypoints in units of frames.~(B) Analyze the movement of key points, and figure out the correlation between swallowing states.~(C) Create an input/output process that can automatically classify swallowing states with video as input.